To Gain More Insights into the Dementia Drugs Market, Browse Summary of the Research Report –
Dementia is a form of disease that affects the functioning of the brain resulting in decline in memory or other thinking skills. Alzheimer’s disease is the most common and largest form of dementia (in over 60% cases), which is observed among people aged 65 years and above. Accumulation of a protein called beta amyloid in the spaces between nerve cells due to genetic mutation is a major cause of dementia. Although dementia is not treatable, symptomatic treatment is followed in all cases. Research is being carried out to develop therapies centered on the role of beta-amyloid in dementia.
The global dementia drugs market was valued at US$ 13,900.0 million in 2017 and is expected to witness a CAGR of 8.4% over the forecast period (2018–2026).
https://www.coherentmarketinsights.com/market-insight/dementia-drugs-market-1664
Dementia is one of the most prevalent neurodegenerative diseases in which patients suffer from various behavioral changes, as a primary symptoms such as decline in memory or other thinking skills and can gets worse as condition progresses. It majorly affects people of aged 65 years and above. Currently, there is no curative therapy available for dementia disease. However, drugs for dementia therapy are in pipeline, which are expected to be launched in the near future, in turn propelling growth of the dementia drugs market.
“We Do Offer Sample of Dementia Drugs Market Report. Kindly go through the follow information in order to access sample copy.”
https://www.coherentmarketinsights.com/insight/request-sample/1664
Increasing aging population along with its associated complications is the major driving factor for growth of the dementia drugs market. For instance, according to Centers of Disease Control and Prevention (CDC), 2013, five million people were suffering from AD and the number is expected to rise up to 14 million by 2050, in the U.S. Moreover, according to World Health Organization (WHO), 2017, around 47 million people suffer from dementia and around 10 million new cases are reported annually. Increasing incidence of dementia coupled with growing demand for therapy is expected to favor growth of the dementia drugs market in the near future.
According to Australian Institute of Health and Welfare (AIHW) estimates, the number of people with dementia is expected to reach to around 400,000 by 2020, and around 900,000 by 2050. Moreover, the National Health and Medical Research Council (NHMRC) is working in collaboration with the Australian Research Council (ARC) to prioritize and fund new dementia research projects and translate research to improve prevention, diagnosis, treatment, and care for dementia patients.
Table of Contents
1. Research Objectives and Assumptions
◦ Research Objectives
◦ Assumptions
◦ Abbreviations
2. Market Purview
◦ Report Description
▪ Market Definition and Scope
◦ Executive Summary
▪ Market Snippet, By Drug Type
▪ Market Snippet, By Distribution Channel
▪ Market Snippet, By Region
◦ Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
◦ Market Dynamics
▪ Drivers
▪ Restraints
▪ Market Opportunities
◦ Impact Analysis
◦ Market Trends
◦ Regulatory Scenario
◦ Reimbursement Scenario
◦ Epidemiology
◦ PEST Analysis
◦ Recent Product Launch
◦ Merger and Acquisition Scenario
Top players in the market
Key players are adopting strategic collaboration, acquisition, and product portfolio expansion to enhance their market share. For instance, Teva Pharmaceutical Industries Ltd. acquired Actavis Generics from Allergan in 2016, for around US$ 40 billion, which also includes the Alzheimer’s portfolio of Actavis Generics. This acquisition boosted revenue of Teva in its fourth quarter of 2016 and first quarter of 2017.
Furthermore, Genentech and AC Immune are also jointly developing anti-amyloid beta antibody crenezumab, which started phase three clinical trial in 2017. They are developing anti-amyloid beta vaccine for Alzheimer’s disease treatment. Furthermore, AC Immune and Janssen Pharmaceutical are also co-developing vaccine for Alzheimer’s treatment.
Research methodology adopted by Coherent Market Insights
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
• Primary Research (Trade Surveys and Experts Interviews)
• Desk Research
• Proprietor Data Analytics Model
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Request A Sample Copy Dementia Drugs Market Report Click here:
https://www.coherentmarketinsights.com/insight/request-sample/1664
Get PDF Research Report Brochure @
https://www.coherentmarketinsights.com/insight/request-pdf/1664
Buy Now this Premium Report to Grow your Business @
https://www.coherentmarketinsights.com/insight/buy-now/1664
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.
Contact Us:
Name: Mr. Raj Shah
Email: [email protected]
Phone: US +12067016702
Country: United States
Visit our Blog: https://hospitalhealthcareblog.wordpress.com/